Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

FLUOXETINE HCL 60 MG TABLET

fluoxetine hcl
$0.2783per EA

Strength

60 mg/1

Manufacturer

Strides Pharma Inc.

NDC

64380090004

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

FLUOXETINE

Approval Type

Generic (ANDA)

FDA Application

ANDA212683

On Market Since

11/8/2024

Pharmacological Classes

Serotonin Reuptake Inhibitor
Serotonin Uptake Inhibitors

Price History

1W

0.0%

1M

-16.6%

3M

-31.9%

6M

-16.6%

1Y

-36.1%

3Y

N/A

5Y

N/A

All

-13.0%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

CITALOPRAM HBR 10 MG TABLET
Generic
00378623101•Mylan Pharmaceuticals Inc.
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
00378623105•Mylan Pharmaceuticals Inc.
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
00904608461•Major Pharmaceuticals
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
13668000901•Torrent Pharmaceuticals Limited
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
13668000905•Torrent Pharmaceuticals Limited
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
13668000909•Torrent Pharmaceuticals Limited
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
42806001901•Epic Pharma LLC
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
42806001910•Epic Pharma LLC
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
65862000501•Aurobindo Pharma Limited
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
65862000505•Aurobindo Pharma Limited
$0.0254
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy